Navrogen wins China patent for NAV-001 cancer antibody-drug conjugate

Navrogen said July 14, 2026, that China granted a patent for NAV-001, its anti-mesothelin antibody-drug conjugate designed for cancers that resist antibody-based therapies. The company says the patent strengthens its global strategy for a drug candidate aimed at hard-to-treat tumor types including breast, colorectal, gastric, lung, mesothelioma, ovarian and pancreatic cancers.

Why it matters: - Navrogen’s patent covers a drug design meant to work in cancers where humoral immunosuppressive, or HIO, factors blunt the effect of antibody-based therapies. - The patent could support Navrogen’s effort to advance NAV-001 in mesothelin-expressing cancers with limited treatment options. - The filing spans multiple cancer types, including breast, colorectal, gastric, lung, mesothelioma, ovarian and pancreatic cancers.

What happened: - Navrogen said China granted patent #ZL2021800659869 for NAV-001, its HIO-refractory anti-mesothelin antibody-drug conjugate. - The patent covers the design and use of NAV-001 to treat mesothelin-expressing, HIO-positive cancers. - The company said the patent was announced July 14, 2026. - Navrogen is based in Cheyney, Pa.

The details: - HIO-positive cancers produce tumor-derived proteins that bind to IgG-type monoclonal antibodies, T-cell engagers and ADCs. - Navrogen says that interaction changes antibody structure and suppresses antibody-mediated killing of target cells. - The company says HIO factors also reduce ADC internalization by cancer cells, which is important for tumor cell killing. - Navrogen says its platform is designed to engineer HIO-refractory antibody-based drugs. - NAV-001 has shown single-dose cures in experimental models of difficult-to-treat, HIO-positive cancers, according to the company. - Navrogen said NAV-001 is its lead experimental program. - Chief Executive Officer Nicholas Nicolaides said NAV-001 is being advanced toward clinical proof-of-concept studies. - Nicolaides said many MSLN-expressing cancers have HIO factors that have limited the effectiveness of other anti-MSLN experimental drugs in clinical trials. - Nicolaides said NAV-001 has shown superior performance compared with many of those agents and can deliver high efficacy at a single low dose.

Between the lines: - The patent adds intellectual-property backing to Navrogen’s effort to position NAV-001 as a differentiated antibody-drug conjugate in a crowded oncology field. - The company is tying the asset to a broader thesis: overcoming tumor-driven immune suppression may improve responses where standard antibody therapies fall short. - Navrogen also appears to be building a paired diagnostics-and-therapeutics strategy around identifying patients whose tumors produce HIO factors.

What's next: - Navrogen plans to move NAV-001 toward clinical proof-of-concept studies. - The company says the patent is part of a global value strategy for therapies targeting HIO-positive cancers. - Navrogen continues to offer diagnostic assays intended to help physicians identify patients whose tumors produce HIO factors.

The bottom line: - The China patent gives Navrogen added protection for a lead cancer drug candidate designed to overcome a key mechanism of resistance to antibody-based treatments.